Latest On bioMérieux S.A (BMXMF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-06-06 05:59 EST | Dividend | A dividend of $0.85 has been announced on Apr 12, 2023. It will be paid Jun 8, 2023 with an ex-dividend date of Jun 6, 2023. | Neutral |  |
| 2022-06-06 05:58 EST | Dividend | A dividend of $0.85 has been announced on Mar 2, 2022. It will be paid Jun 8, 2022 with an ex-dividend date of Jun 6, 2022. | Neutral | |
| 2022-03-03 04:32 EST | News | bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-02 10:22 EST | News | bioMérieux S.A. GAAP EPS of €5.06, revenue of €3.37M | N/A | |
| 2021-10-21 21:57 EST | News | bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-09-01 15:14 EST | News | bioMérieux S.A. reports 1H results | N/A | |
| 2021-08-19 19:04 EST | News | bioMérieux: Pioneering In Vitro Diagnostics | N/A | |
| 2021-06-04 06:10 EST | Dividend | A dividend of $0.62 has been announced on Feb 24, 2021. It will be paid Jun 8, 2021 with an ex-dividend date of Jun 4, 2021. | Neutral | |
| 2021-02-28 16:49 EST | News | bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-02-26 16:59 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-24 18:26 EST | News | bioMérieux reports FY 2020 results | N/A | |
| 2020-11-26 22:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 01:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 15:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 07:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-04 15:20 EST | News | bioMérieux SA (BMXMF) CEO Alexandre Mérieux on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-09-03 10:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-03 08:02 EST | News | bioMérieux S.A. 2020 Q2 - Results - Earnings Call Presentation | N/A | |
| 2020-08-14 11:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 14:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 18:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 06:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 23:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 14:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 19:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-14 05:59 EST | Dividend | A dividend of $0.19 has been announced on Feb 26, 2020. It will be paid Jul 16, 2020 with an ex-dividend date of Jul 14, 2020. | Neutral | |
| 2020-07-09 11:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 02:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 06:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 08:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 07:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 02:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 07:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 18:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-20 06:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-17 01:30 EST | News | Race in full stride for tests to identify coronavirus illness | N/A | |
| 2020-04-14 14:42 EST | News | Race in full-stride for tests to identify coronavirus illness | N/A | |
| 2020-04-09 22:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-08 22:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-03 22:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-25 22:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-01 03:13 EST | News | bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2019 Results - Earnings Call Transcript | N/A | |
| 2020-02-28 06:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 00:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-22 01:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-21 01:05 EST | Financials | Company financials have been released. | Neutral | |
About bioMérieux S.A (BMXMF):
bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that identifies microorganism present in biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as pathological markers. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test, as well as services for clinical and industrial laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
General
- Name bioMérieux S.A
- Symbol BMXMF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDiagnostics & Research
- Full Time Employees 12,800
- Fiscal Year EndDecember
- Web URLhttp://www.biomerieux.com
View More
Valuation
- Trailing PE 46.38
- Forward PE 29.85
- Price/Sales (Trailing 12 Mt.) 4.05
- Price/Book (Most Recent Quarter) 5.18
- Enterprise Value Revenue 4.73
- Enterprise Value EBITDA 19.42
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 13%
- Return on Assets 10%
- Return on Equity 17%
- Earnings Per Share $2.68
- Revenue Per Share $0
- Gross Profit 1.75 billion
- Quarterly Earnings Growth 17.3%
View More
ESG Rating
Highlights
- Market Capitalization 14.97 billion
- PEG Ratio 2.17
- Book Value Per Share $18.13
View More
Share Statistics
- Shares Outstanding 118.35 million
- Shares Float 42.31 million
- % Held by Insiders 6874%
- % Held by Institutions 21.08%
View More
Technicals
- Beta -0.22
- 52 Week High $170.55
- 52 Week Low $88.97
- 50 Day Moving Average 140.47
- 200 Day Moving Average 145.84
View More
Dividends
- Forward Annual Dividend Rate $0.39
- Forward Annual Dividend Yield 0.36%
- Payout Ratio 7%
- Dividend Date 2017-06-08
- ExDividend Date 2019-06-04
- Dividend Per Share $0.39
- Dividend Yield 0%
View More
bioMérieux S.A (BMXMF) Dividend Calendar:
BMXMF's last dividend payment was made to shareholders on June 8, 2017.
bioMérieux S.A pays out 7% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
bioMérieux S.A (BMXMF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | $1.19 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | $1.14 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | $0.82 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $699.85 million | $0.80 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $699.85 million | $0.63 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $637.55 million | $0.61 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $637.55 million | $0.67 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $626.05 million | $0.66 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $626.05 million | $0.59 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $584.6 million | $0.60 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $584.6 million | $0.66 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $576.95 million | $0.70 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $576.95 million | $0.69 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $567.15 million | $0.68 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $567.15 million | $0.49 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $551.2 million | $0.46 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $551.2 million | $0.42 | $0.00 | |
| 2016-06-30 | 2016-09-30 | $0.44 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | $0.40 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | $0.41 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | $0.23 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $0.24 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | $0.28 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | $0.27 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | $0.43 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | $0.45 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $0.29 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.29 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.49 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.48 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $0.44 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.43 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $0.31 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | $0.30 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $0.42 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.45 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.46 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $0.48 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.46 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.44 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.49 | $0.00 |
bioMérieux S.A (BMXMF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 97.7 million |
| Income Before Tax | N/A | N/A | N/A | N/A | 86.25 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 197.8 million |
| Gross Profit | N/A | N/A | N/A | N/A | 378.3 million |
| Ebit | N/A | N/A | N/A | N/A | 95.15 million |
| Operating Income | N/A | N/A | N/A | N/A | 95.15 million |
| Income Tax Expense | 36.9 million | 36.9 million | 23.85 million | 23.85 million | 20.75 million |
| Total Revenue | N/A | N/A | N/A | N/A | 699.85 million |
| Cost of Revenue | N/A | N/A | N/A | N/A | 321.55 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -8.9 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | 65.5 million |
| Net Income Applicable to Common Shares | 115.75 million | 115.75 million | 86.45 million | 86.45 million | 66.15 million |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -50000 | -50000 | -1.15 million |
| Change to Liabilities | -5.05 million | -5.05 million | 12.2 million | 12.2 million | 4.25 million |
| Total Cash Flow from Investing Activities | -62.45 million | -62.45 million | -56.8 million | -56.8 million | -84.3 million |
| Net Borrowings | N/A | N/A | -29.25 million | -29.25 million | -5.35 million |
| Total Cash Flow from Financial Activities | N/A | N/A | -29.35 million | -29.35 million | -37.6 million |
| Change to Operating Activities | 27.05 million | 27.05 million | 6.8 million | 6.8 million | 7.45 million |
| Change in Cash | N/A | N/A | 28.55 million | 28.55 million | -35.65 million |
| Total Cash from Operating Activities | 130.35 million | 130.35 million | 116.3 million | 116.3 million | 87.65 million |
| Depreciation | N/A | N/A | 51.55 million | 51.55 million | 43.2 million |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | -5.85 million | -5.85 million | -29.65 million |
| Change to Account Receivables | N/A | N/A | -29.35 million | -29.35 million | 700000 |
| Other Cash Flow from Financing Activities | 88.25 million | 88.25 million | 150000 | 150000 | -11.85 million |
| Change to Net Income | 800000 | 800000 | 19.65 million | 19.65 million | -13.4 million |
| Capital Expenditures | N/A | N/A | 74.6 million | 74.6 million | 61.65 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 1.53 billion |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 2.2 billion |
| Other Current Liabilities | 587.8 million | 587.8 million | N/A | N/A | 519.6 million |
| Total Assets | N/A | N/A | N/A | N/A | 3.78 billion |
| Common Stock | 12 million | 12 million | 12 million | 12 million | 12 million |
| Other Current Assets | 100000 | 100000 | N/A | N/A | N/A |
| Retained Earnings | 404.4 million | 404.4 million | 172.9 million | 172.9 million | 272.8 million |
| Other Liabilities | 170.3 million | 170.3 million | 186.6 million | 186.6 million | 203.5 million |
| Other Assets | 86.9 million | 86.9 million | 113.7 million | 113.7 million | 115.2 million |
| Cash | N/A | N/A | N/A | N/A | 275 million |
| Total Current Liabilities | 923.8 million | 923.8 million | N/A | N/A | 1.17 billion |
| Other Stockholder Equity | -100000 | -100000 | N/A | N/A | N/A |
| Property, Plant & Equipment | 1.07 billion | 1.07 billion | 1.04 billion | 1.04 billion | 1.03 billion |
| Total Current Assets | 1.66 billion | 1.66 billion | N/A | N/A | 1.44 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 42.1 million |
| Net Tangible Assets | 1.37 billion | 1.37 billion | 1.22 billion | 1.22 billion | 1.04 billion |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | 153.7 million |
| Inventory | 541.9 million | 541.9 million | N/A | N/A | 494.7 million |
| Accounts Payable | 207.1 million | 207.1 million | N/A | N/A | 211.9 million |
bioMérieux S.A (BMXMF) Chart:
bioMérieux S.A (BMXMF) News:
Below you will find a list of latest news for bioMérieux S.A (BMXMF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
bioMérieux S.A (BMXMF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
bioMérieux S.A (BMXMF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|